

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 July 2023 (06.07.2023)



(10) International Publication Number
WO 2023/130023 A1

- (51) **International Patent Classification:**
C07D 205/12 (2006.01)
- (21) **International Application Number:**
PCT/US2022/082554
- (22) **International Filing Date:**
29 December 2022 (29.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/294,747 29 December 2021 (29.12.2021) US
- (71) **Applicant:** **PSY THERAPEUTICS, INC.** [US/US]; 28
Atlantic Avenue, Suite 129, Boston, MA 02110 (US).
- (72) **Inventor:** **HOOKER, Jacob, Matthew**; 14 Ware Rd.,
Winchester, MA 01890 (US).
- (74) **Agent:** **LEVY, Seth, D.** et al.; Nixon Peabody LLP, 300
South Grand Avenue, Suite 4100, Los Angeles, CA 90071
(US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** INHIBITING MONOACYLGLYCEROL LIPASE (MAGL)

(57) **Abstract:** Provided herein are 1 H-pyrazol-5-yl)-2-azaspiro[3.3]heptan-2-yl methanone compounds substituted with aryl and pyrazolyl moieties, further substituted, for inhibiting monoacylglycerol lipase (MAGL), utilized in the treatment of a MAGL-mediated disease or disorder i.e., neurodegenerative diseases, pain, and inflammatory diseases or conditions, as well as cancer, and related methods of making and using the compounds.

